1. Home
  2. KPTI vs SAMG Comparison

KPTI vs SAMG Comparison

Compare KPTI & SAMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$6.75

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Logo Silvercrest Asset Management Group Inc.

SAMG

Silvercrest Asset Management Group Inc.

HOLD

Current Price

$15.27

Market Cap

112.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
KPTI
SAMG
Founded
2008
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
94.6M
112.1M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
KPTI
SAMG
Price
$6.75
$15.27
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$22.17
N/A
AVG Volume (30 Days)
174.4K
37.8K
Earning Date
11-03-2025
10-30-2025
Dividend Yield
N/A
5.53%
EPS Growth
N/A
N/A
EPS
N/A
0.72
Revenue
$142,530,000.00
$125,322,000.00
Revenue This Year
$3.82
$3.44
Revenue Next Year
$3.18
$9.39
P/E Ratio
N/A
$21.14
Revenue Growth
N/A
4.23
52 Week Low
$3.51
$13.23
52 Week High
$12.45
$19.20

Technical Indicators

Market Signals
Indicator
KPTI
SAMG
Relative Strength Index (RSI) 63.89 62.98
Support Level $5.70 $14.48
Resistance Level $7.48 $15.52
Average True Range (ATR) 0.45 0.46
MACD 0.16 0.17
Stochastic Oscillator 69.78 86.07

Price Performance

Historical Comparison
KPTI
SAMG

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About SAMG Silvercrest Asset Management Group Inc.

Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.

Share on Social Networks: